english.prescrire.org > Spotlight > Archives : 2021 > In the September issue of Prescrire International - Psoriasis and ixekizumab: turn first to standard systemic treatments

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2021 : 1 | 30 | 60

In the September issue of Prescrire International - Psoriasis and ixekizumab: turn first to standard systemic treatments

FREE DOWNLOAD There is no strong evidence that ixekizumab has greater efficacy than methotrexate in patients with psoriasis. In addition, its adverse effects are less well established than those of standard treatments, particularly in the long term.
Full text available for free download.

Summary

  • In a randomised trial in 108 adults with moderate to severe plaque psoriasis who had never received systemic therapy, subcutaneous ixekizumab (an interleukin-17A inhibitor) appeared to have greater efficacy than oral methotrexate in achieving short-term clearance of lesions.
     
  • However, these results are not robust, due to the lack of blinding and the imbalance in patient characteristics between the groups.

©Prescrire 1 September 2021

Source: "Psoriasis and ixekizumab. Turn first to standard systemic treatments" Prescrire International 2021; 30 (229): 217. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >